Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 131

Results For "ABLE"

4900 News Found

Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr
News | August 11, 2024

Zydus Lifesciences Q1 FY25 revenue up 21% YoY to reach Rs. 6,207.5 Cr

Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues


Health Ministry launches 2nd phase of Mass Drug Administration Campaign 2024 to eliminate Lymphatic Filariasis
Policy | August 11, 2024

Health Ministry launches 2nd phase of Mass Drug Administration Campaign 2024 to eliminate Lymphatic Filariasis

The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh


HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
News | August 11, 2024

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better


Merck's aarogya health program positively impacts communities in Patalganga
Healthcare | August 11, 2024

Merck's aarogya health program positively impacts communities in Patalganga

Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness


Allergan Aesthetics drives India’s potential in the global aesthetic market
News | August 11, 2024

Allergan Aesthetics drives India’s potential in the global aesthetic market

The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020


Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr
News | August 11, 2024

Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr

Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses


IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
News | August 10, 2024

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24


Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
News | August 10, 2024

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.


AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25
News | August 09, 2024

AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25

The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years